SS-31 (Elamipretide): Mechanism, Evidence, and Dosing Protocols

Research disclaimer: SS-31 is sold for research purposes only and is not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Animal studies plus Phase II human trials for specific cardiac and genetic mitochondrial disease indications (as Elamipretide). The human clinical data exists but is for pathological conditions, not longevity or general metabolic use. Supply is limited; quality control is a significant concern.

SS-31 (also known as Elamipretide, MTP-131, and Bendavia) reached Phase II clinical trials through Stealth BioTherapeutics — a company that subsequently encountered serious financial difficulties, with much of its pipeline discontinued. The human trial data that exists is real and informative. The commercial pathway for the compound has not progressed to approval.

What Is SS-31?

SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2, where Dmt = 2’,6’-dimethyltyrosine) developed by Hazel Szeto at Cornell University as part of a series of Szeto-Schiller (SS) peptides designed to target mitochondrial membranes. The “SS” designation reflects the Szeto-Schiller nomenclature.

The design is deliberate and elegant: the alternating aromatic-cationic amino acid pattern of SS-31 allows it to traverse membranes and concentrate specifically in the inner mitochondrial membrane — not randomly, but directed by the high cardiolipin content of that membrane. Once there, it achieves concentrations approximately 1,000-fold higher than in the cytoplasm.

Molecular weight is 638.8 Da (free base) or 807.0 Da (tetrahydrochloride salt form). This small size facilitates membrane penetration.

Mechanism of Action

Cardiolipin Binding and Protection (Primary)

Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane (IMM), where it constitutes approximately 20% of the total phospholipid content. It is essential for organising the electron transport chain (ETC) complexes I–V into functional supercomplexes. Without intact cardiolipin, the ETC complexes dissociate and electron transport efficiency plummets.

With age, cardiolipin oxidises — primarily because the IMM is in close proximity to reactive oxygen species (ROS) generated by the ETC itself. Oxidised cardiolipin:

1. Loses its ability to anchor ETC supercomplex organisation
2. Triggers cytochrome c release from the IMM (initiating apoptosis)
3. Impairs ATP synthase function
4. Increases ROS production (creating a feed-forward oxidative cycle)

SS-31 binds to cardiolipin with high affinity and protects it from oxidation. This preserves ETC supercomplex organisation, restores electron transport efficiency, reduces ROS generation, and prevents cytochrome c release.

Electron Transport Chain Efficiency Restoration

In aged mitochondria where cardiolipin oxidation has already occurred, SS-31 treatment restores ETC efficiency — producing more ATP per unit of oxygen consumed and generating less ROS as a byproduct. This has been demonstrated in aged rodent mitochondria, aged human skeletal muscle biopsies (ex vivo), and in animal models of age-related heart failure.

ATP Production Enhancement

Downstream of ETC efficiency restoration, SS-31 increases cellular ATP production. This is particularly relevant to high-energy-demand tissues: heart, skeletal muscle, brain, and kidney — exactly the tissues where age-related mitochondrial dysfunction produces the greatest functional consequence.

Anti-apoptotic Effect

By preventing cytochrome c release from the IMM (a consequence of cardiolipin oxidation), SS-31 blocks the intrinsic apoptosis pathway. This is relevant to ischaemic injury (heart, kidney, brain) where massive apoptotic cell death follows reperfusion.

What the Evidence Actually Shows

Heart Failure with Preserved Ejection Fraction (HFpEF)

Stealth BioTherapeutics ran a Phase II trial (MMAD trial) of subcutaneous Elamipretide in HFpEF. Results showed:

• Significant improvement in 6-minute walk distance (exercise capacity)
• Improvement in patient-reported quality of life scores
• Favourable safety profile

This is real Phase II human data in a cardiovascular indication where mitochondrial dysfunction is a central pathophysiological driver.

Barth Syndrome

Barth syndrome is a rare X-linked genetic disorder caused by mutations in tafazzin — the enzyme that remodels cardiolipin — resulting in severely dysfunctional cardiolipin and consequent heart failure, skeletal muscle weakness, and growth retardation. SS-31’s mechanism of protecting existing cardiolipin is directly relevant.

Phase II trial (TAZPOWER) showed significant improvements in exercise capacity and muscle function in Barth syndrome patients on Elamipretide. This is the most direct human validation of the cardiolipin mechanism.

Leber’s Hereditary Optic Neuropathy (LHON)

A Phase II trial for this mitochondrial optic neuropathy showed improvement in visual acuity in some patients. This expanded the evidence beyond cardiac indications to neurological mitochondrial disease.

Aged Animal Models

Multiple studies across research groups show SS-31 in aged rodents produces:

• Improved exercise capacity and grip strength
• Improved cardiac function (reduced stiffness, improved relaxation)
• Improved kidney function
• Reduced markers of age-related inflammation
• Extended healthy lifespan in some models

These animal findings are what drive interest in SS-31 for general longevity applications beyond its specific disease indications.

What Is Not Established

• Longevity or metabolic benefit in healthy humans — zero data
• Effective dose in humans for non-pathological applications (Phase II doses were IV/SC in disease contexts)
• Whether the animal longevity data translates to meaningful human longevity benefit
• Long-term safety beyond trial durations
• Bioavailability from researcher-grade SC injection vs clinical-grade preparation

The Supply Problem

This deserves explicit treatment. Stealth BioTherapeutics filed for bankruptcy in 2022 after the Phase IIb PROGRESS-HFpEF trial did not meet its primary endpoint (a single-dose IV study with different methodology than the prior positive trials). The compound’s regulatory pathway is uncertain.

Research suppliers offering SS-31 are synthesising it independently. The synthesis is complex (D-amino acids, non-standard Dmt residue), and quality control is genuinely challenging. There is no reference pharmaceutical standard available for comparison. Researchers sourcing SS-31 should treat quality verification as a primary concern, not an afterthought.

Dosing Protocols (Research Context)

Clinical trial doses and routes varied considerably:

• Barth syndrome trial: 40 mg/day SC
• HFpEF MMAD trial: 40 mg/day SC
• Earlier IV trials: 0.005–0.25 mg/kg IV infusion

Research community protocols extrapolated from this:

The 40 mg/day clinical dose exceeds what most researcher protocols use. Whether lower doses produce meaningful benefits for non-pathological applications is unknown.

Reconstitution: SS-31 is supplied in lyophilised form. Reconstitute with sterile or bacteriostatic water to target concentration. Confirm with supplier which salt form is supplied (free base vs tetrahydrochloride) before calculating doses.

Storage: Lyophilised: −20°C. Reconstituted: refrigerate 2–8°C, use within 30 days.

Summary

SS-31 is the most mechanistically specific mitochondrial therapeutic in this review series — it targets a single molecular event (cardiolipin oxidation) that sits at the convergence of ROS damage, ETC dysfunction, and apoptosis initiation in aged mitochondria. The human clinical evidence for specific pathological indications is real and meaningful. The supply challenges following Stealth BioTherapeutics’ difficulties are a genuine practical barrier. For researchers working in mitochondrial ageing, this is scientifically the most important compound in the space — and the one that requires the greatest due diligence in sourcing.

See also: Mitochondrial Stack: MOTS-c + SS-31 · MOTS-c research review